{"title":"Phenotype-informed lipid management across the care continuum of hypertriglyceridemia-associated acute pancreatitis: A narrative review.","authors":"Zhiyi Zhang, Gang Peng, Yuyang Zhou, Yumeng Lu, Fulin Tao, Chengbao Xu","doi":"10.1016/j.jacl.2026.10.013","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hypertriglyceridemia-associated acute pancreatitis (HTG-AP) complicates severe hypertriglyceridemia, particularly chylomicronemia, and often recurs. Neither acute stabilization nor an in-hospital fall in triglycerides (TG) addresses the metabolic disorder that persists after discharge. Management must also characterize the chylomicronemia phenotype, correct secondary causes, and maintain lipid control.</p><p><strong>Sources of material: </strong>English- and Chinese-language literature was identified primarily through PubMed, with supplementary searches of the Cochrane Library, Web of Science, and the Chinese Medical Journals Full-text Database. Regulatory documents and prescribing information supplemented clinical studies and guidelines. Evidence was assessed for TG response, patient-important outcomes, safety, and applicability.</p><p><strong>Abstract of findings: </strong>HTG-AP involves TG-rich lipoprotein accumulation, lipotoxic injury, and impaired pancreatic microcirculation. Acute TG lowering has not consistently improved organ failure or survival in comparative studies. Long-term decisions require assessment of familial or multifactorial chylomicronemia, persistence of extreme TG, pancreatitis alarm features, and secondary causes. Diet and conventional lipid-lowering therapy remain the foundation. Therapies targeting apolipoprotein C-III reduce pancreatitis events in selected populations; olezarsen has evidence in severe hypertriglyceridemia as well as familial chylomicronemia. Evidence for recurrence prevention is insufficient for therapies targeting angiopoietin-like proteins 3 and 4 or fibroblast growth factor 21.</p><p><strong>Conclusion: </strong>This review proposes a clinical approach linking acute care to reassessment of lipid phenotype, correction of secondary causes, and recurrence prevention. The integrated pathway has not been prospectively validated. Treatment decisions should distinguish biochemical response from clinical benefit and pancreatitis risk from atherosclerotic risk.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":6.9000,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical lipidology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jacl.2026.10.013","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Hypertriglyceridemia-associated acute pancreatitis (HTG-AP) complicates severe hypertriglyceridemia, particularly chylomicronemia, and often recurs. Neither acute stabilization nor an in-hospital fall in triglycerides (TG) addresses the metabolic disorder that persists after discharge. Management must also characterize the chylomicronemia phenotype, correct secondary causes, and maintain lipid control.
Sources of material: English- and Chinese-language literature was identified primarily through PubMed, with supplementary searches of the Cochrane Library, Web of Science, and the Chinese Medical Journals Full-text Database. Regulatory documents and prescribing information supplemented clinical studies and guidelines. Evidence was assessed for TG response, patient-important outcomes, safety, and applicability.
Abstract of findings: HTG-AP involves TG-rich lipoprotein accumulation, lipotoxic injury, and impaired pancreatic microcirculation. Acute TG lowering has not consistently improved organ failure or survival in comparative studies. Long-term decisions require assessment of familial or multifactorial chylomicronemia, persistence of extreme TG, pancreatitis alarm features, and secondary causes. Diet and conventional lipid-lowering therapy remain the foundation. Therapies targeting apolipoprotein C-III reduce pancreatitis events in selected populations; olezarsen has evidence in severe hypertriglyceridemia as well as familial chylomicronemia. Evidence for recurrence prevention is insufficient for therapies targeting angiopoietin-like proteins 3 and 4 or fibroblast growth factor 21.
Conclusion: This review proposes a clinical approach linking acute care to reassessment of lipid phenotype, correction of secondary causes, and recurrence prevention. The integrated pathway has not been prospectively validated. Treatment decisions should distinguish biochemical response from clinical benefit and pancreatitis risk from atherosclerotic risk.
背景:高甘油三酯血症相关性急性胰腺炎(HTG-AP)可并发严重高甘油三酯血症,特别是乳糜微粒血症,并且经常复发。急性稳定和住院甘油三酯(TG)下降都不能解决出院后持续存在的代谢紊乱。管理还必须确定乳糜微粒血症的表型,纠正继发原因,并保持脂质控制。资料来源:英文和中文文献主要通过PubMed检索,辅以Cochrane图书馆、Web of Science和Chinese Medical Journals全文数据库的检索。规范性文件和处方信息补充了临床研究和指南。评估TG反应、患者重要结局、安全性和适用性的证据。研究结果摘要:HTG-AP涉及富含tg的脂蛋白积累、脂毒性损伤和胰腺微循环受损。在比较研究中,急性TG降低并没有一致地改善器官衰竭或生存率。长期决定需要评估家族性或多因素乳糜小血症、持久性极端TG、胰腺炎报警特征和继发原因。饮食和传统的降脂疗法仍然是基础。针对载脂蛋白C-III的治疗可减少特定人群的胰腺炎事件;Olezarsen在严重的高甘油三酯血症和家族性乳糜小血症中有证据。针对血管生成素样蛋白3和4或成纤维细胞生长因子21的治疗预防复发的证据不足。结论:本综述提出了一种将急性护理与脂质表型重新评估、纠正继发原因和预防复发联系起来的临床方法。整合途径尚未得到前瞻性验证。治疗决定应区分生化反应与临床获益,胰腺炎风险与动脉粥样硬化风险。
期刊介绍:
Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner.
Sections of Journal of clinical lipidology will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.